Certara Services Archives

Blog

Using Model-based Meta-analysis to Inform Neuropathic Pain Drug Development

Model-based Meta-analysis is a framework to compare drugs used to treat diabetic peripheral neuropathy, post-herpetic…

CertaraDecember 19, 2019

Blog

ICER’s Unsupported Drug Price Increase Report: An Analysis

We analyze the drug-price watchdog, ICER’s (Institute for Clinical and Economic Review) “Report on Unsupported…

CertaraOctober 24, 2019

On-Demand Webinar

Innovative Solutions for Fast-Tracking Drugs for Rare Diseases

This webinar discussed which pharmaceutical payer strategies work and which don't in our rapidly changing…

CertaraAugust 10, 2019

Brochure

Evidence and Access Overview

Discover Certara’s holistic approach to market access.

CertaraMay 21, 2019

On-Demand Webinar

Advanced Analytics Using RWD Mitigates Risks in AD Drug Development & Reimbursement

This webinar explained how advanced analytics using real-world data can mitigate challenges in Alzheimer’s disease…

CertaraMay 13, 2019

Blog

Trends for Market Access, HEOR, and Real World Evidence

This blog reviews trends for using health economics and outcomes research and real-world evidence to…

CertaraMay 10, 2019

Blog

Real World Evidence Marches Forward in Drug Development

The end of 2018 ushered in a flurry of new regulatory guidance and sponsor enthusiasm…

CertaraMarch 20, 2019

Publication

Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond

Apixaban is an orally available, direct, selective inhibitor of the coagulation factor Xa that reversibly…

CertaraJune 2, 2018

Publication

Model-informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

CertaraFebruary 15, 2018

White Paper

Drug Asset Evaluation: Increasing “Probability of Success” of a Deal

Certara’s due diligence/asset evaluation teams are comprised of drug development and commercialization experts who advise…

CertaraAugust 24, 2017

Certara Services

Using Model-based Meta-analysis to Inform Neuropathic Pain Drug Development

ICER’s Unsupported Drug Price Increase Report: An Analysis

Innovative Solutions for Fast-Tracking Drugs for Rare Diseases

Evidence and Access Overview

Advanced Analytics Using RWD Mitigates Risks in AD Drug Development & Reimbursement

Trends for Market Access, HEOR, and Real World Evidence

Real World Evidence Marches Forward in Drug Development

Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond

Model-informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

Drug Asset Evaluation: Increasing “Probability of Success” of a Deal

Newsletter sign up

Quick links

Solutions

Contact